News AACR 2025: Quintet of investigational oncological drugs puts... Ascentage Pharma, specialising in haematological malignancies, has presented results from five preclinical studies at AACR 2025.
Oncology Driving innovation in multiple myeloma to improve the patien... Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies.1
News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face